🟢 Health ETF (IYH) is trading 5.9% up in pre-market after FDA approval for Mounjaro’s cardiovascular-risk reduction

IYH is trading at $76.90 (+5.88%) in pre-market after Eli Lilly received FDA approval for Mounjaro to reduce cardiovascular-event risk.

• The approval supports IYH’s largest holding, Eli Lilly, at roughly 16%.
• Revolution Medicines gained sector attention after FDA approval of Rasonque for advanced pancreatic cancer, though its IYH weighting is only about 0.6%.
• Mixed futures suggest the move is primarily healthcare-specific rather than broad-market driven.